Gonadotropin releasing hormone (GnRH) agonist therapy for reduction of leiomyoma volume.
A patient with menorrhagia, dysmenorrhea, and an enlarged uterus was treated with a GnRH agonist for leiomyoma volume reduction. A laser-assisted myomectomy yielded five tumors that did not appear to be well demarcated and had a combined weight of only 30 g. Postoperative pathologic evaluation revealed leiomyosarcoma with 22 mitoses per 10 high-power fields. The 8-month delay in therapy was associated with Stage IV, grade 3 disease at diagnosis. In rare cases GnRH agonist therapy may palliate symptoms and delay definitive surgical therapy of leiomyosarcoma, resulting in more advanced disease at diagnosis.
Department of Obstetrics and Gynecology, St. Luke's Hospital, Kansas City, Missouri 64111.
N J
NJ
Murphy
D L
DL
Wallace
D000328:Adult; D005260:Female; D006801:Humans; D007889:Leiomyoma / Q000188:drug therapy* / Q000601:surgery; D016729:Leuprolide / Q000627:therapeutic use*; D014594:Uterine Neoplasms / Q000188:drug therapy* / Q000601:surgery
D016729:Leuprolide